Treatment options for ocular adnexal lymphoma (OAL)
- PMID: 20054418
- PMCID: PMC2801639
- DOI: 10.2147/opth.s5828
Treatment options for ocular adnexal lymphoma (OAL)
Abstract
Most lymphomas that involve the ocular adnexal structure are low grade, B cell, non-Hodgkin's lymphomas. The treatment depends upon the grade and stage of the disease. High grade lymhoma requires treatment with systemic chemotherapy whereas the localized low grade (extranodal marginal zone lymphoma) can be successfully managed with local radiotherapy. Chlamydia psittaci infection is associated with low grade ocular lymphoma; however there is wide geographic variation in the strength of this association. Blanket antibiotic therapy is not advised unless there is proof of an infective agent. The monoclonal antibody, rituximab, may be successful for CD20 positive lymphoma, although it is likely that rituximab will have better long-term results when used in combination with systemic chemotherapy.
Keywords: Chlamydia psittaci; chemotherapy; extranodal marginal zone lymphoma; mucosa associated lymphoid tissue; ocular adnexal lymphoma; radiotherapy; rituximab.
References
-
- Shields CL, Shields JA, Carvalho C, Rundle P, Smith AF. Conjunctival lymphoid tumors: clinical analysis of 117 cases and relationship to systemic lymphoma. Ophthalmology. 2001;108:979–984. - PubMed
-
- Tanimoto K, Kaneko A, Suzuki S, et al. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol. 2006;17:135–140. - PubMed
-
- Restrepo A, Raez LE, Byrne GE, Jr, et al. Is central nervous system prophylaxis necessary in ocular adnexal lymphoma? Crit Rev Oncog. 1998;9:269–273. - PubMed
-
- Fung CY, Tarbell NJ, Lucarelli MJ, et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys. 2003;57:1382–1391. - PubMed
LinkOut - more resources
Full Text Sources